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Gene expression Analyses in Non 
Muscle Invasive Bladder Cancer 
Reveals a Role for Alternative 
Splicing and Tp53 Status
Marta Dueñas1,2,3, Andrés Pérez-Figueroa  4, Carla oliveira5, Cristian Suárez-Cabrera1,2,3, 
Abel sousa5, Patricia oliveira5, Felipe Villacampa2,3,6, Jesús M. paramio  1,2,3 & 
Mónica Martínez-Fernández1,2,3,7
Non-muscle invasive bladder cancer (NMIBC) represents a crucial problem for the national health care 
systems due to its high rates of recurrence and the consequent need of frequent follow-ups. Here, gene 
expression analyses in patients diagnosed as NMIBC were performed to determine those molecular 
pathways involved in tumor initiation, finding that both MYC and E2F are up regulated and helps to 
tumor initiation and progression. Our results also support an important involvement of alternative 
splicing events, modifying key pathways to favour bladder tumor evolution. Finally, since MDM2 
showed differential exon usage, mutations in TP53 and its protein expression have been also studied 
in the same patients. Our data support that recurrence is epigenetically mediated and favoured by an 
increase protein expression of TP53, which appears more frequently mutated in advanced stages and 
grades, being associated to a worse prognosis. Therefore, TP53 mutational status could be used as a 
potential biomarker in the first stages of NMIBC to predict recurrence and prognosis.
Bladder cancer (BC) is the tenth most frequently diagnosed tumor worldwide and entails the highest cost per 
patient among all types of cancers1. At diagnosis, tumor appears frequently as non-muscle invasive bladder can-
cer (70% NMIBC; Ta-T1 stages), while a lower percentage is already invasive into the bladder muscle layers 
(30% MIBC; T2-T4 stages). In these last cases, the gold standard for treatment is a radical cystectomy preceded, 
when possible, by cisplatin-based chemotherapy with the aim of preventing the frequent metastases. In the case 
of NMIBC, it has a priory higher life expectancy, and its treatment consists of a transurethral resection (TUR), 
sometimes followed by bladder instillations of BCG or mitomycin. In spite of this invasive treatment, NMIBC has 
extremely high rates of recurrences (70–80%), and some recurrences can even appear with an advanced tumor 
stage and/or grade (30%) with the associated worse outcome. Currently, the only procedure to monitor these 
patients and to prevent recurrence is a frequent cystoscopy. Unfortunately, this impairs patients’ life quality and 
has high costs for the national health systems. Although important efforts have been recently done2–5, there is still 
an urgent need for a better understanding of the molecular mechanisms behind the high rates of recurrence and 
for a predictable biomarker.
Gene expression analyses in NMIBC patients pointed towards a role of alternative splicing (AS) for tumor 
initiation. AS events in the human genome provides the capability to diversify the proteome through the alter-
native combination of exons from a single gene to form different mature mRNAs and protein products. Using 
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different transcriptomic technologies, it is possible to study gene expression at the exon resolution, allowing the 
detection of AS events that could be altering cancer key pathways. In fact, recent studies have shown that AS is 
frequently altered in several tumor types and that the new aberrant isoforms can act as cancer drivers, affecting to 
fundamental oncogenic processes such as angiogenesis, proliferation, immune escape, apoptosis, or metastasis6,7. 
Although different associations between particular AS events and patient prognosis have been reported in several 
tumor types8,9, little is still known in the case of BC10–12. Here, we have carried out the first comprehensive AS 
related study in a cohort of 82 NMIBC patients (Fig. S1A). Our results support a key role of AS able of modulat-
ing expression of crucial pathways, favouring tumor progression. In addition, following the results found, single 
nucleotide variations in TP53 gene were analysed using Next Generation Sequencing. This is especially interesting 
since TP53 has been frequently detected as mutated and related to chemo-resistance in MIBC13–16, but its role 
and status in NMIBC is still to be clarified. Our results support that TP53 mutations and expression can be used 
to determine patients’ prognosis.
Results
Alternative splicing events in BC. Affymetrix HuGene-1_0-st-v1 arrays were used to interrogate 10 nor-
mal and 28 bladder cancer samples (GSE382644). As shown in Fig. 1A, differential gene expression in 2574 tran-
scripts could clearly differentiate normal versus tumor samples. Gene Ontology Biological Processes (GOBP) 
analyses on these transcripts revealed, among other processes, an important role of AS events and RNA pro-
cessing (Fig. 1B). Expression of genes differentially expressed was compared to those gene-sets included in the 
Oncogenic Molecular Signatures Database (MSigDB) frequently deregulated in cancer. We found that genes with 
differential expression matched with signatures of key oncogenic pathways such as those upregulated by Shh 
stimulation, MYC overexpression, E2F1 upregulation, or by Rb1-Rbl2 ablation (Fig. 1C). In agreement, using 
ChEA, Transfac, and Encode Transcription Factor databases, we also observed that these deregulated genes pre-
sented binding motifs for both MYC and E2Fs transcription factors (Fig. 1D). To further understand the role 
Figure 1. (A) Differential gene expression between normal and bladder cancer samples using Affymetrix 
HuGene-1_0-st-v1 arrays. (B) Gene Ontology Biological Processes (GOBP) analyses of the transcripts 
showing statistically significant differences. (C) Genesets often de-regulated in cancer that overlaps with the 
genesets showing differences between normal and tumor samples using the Molecular Signatures Database 
(MSigDB) from GSEA software. (D) Those de-regulated genes share binding motifs for MYC and E2Fs 
transcription factors, according with ChEA, Transfac, and Encode Transcription Factor databases. (E) Genes 
whose expression is correlated with the expression of the ESRP2 splicing factor. (F) Genes whose expression is 
correlated with the expression of the PRMT5 splicing factor. (G) Genes whose expression is correlated with the 
expression of the RBM4 splicing factor.
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of AS, we decided to test which genes showed a statistical expression correlation with different splicing factors 
expression included in the array, such as ESRP2, PRMT5, and RBM4. Using a PTM analysis, we found a high 
statistically significant correlation between the expression of these splicing genes and important cancer-related 
transcription factors (Fig. 1E–G), including genes involved in cancer (ETS1, XRN2, VDR), in epigenetic mecha-
nisms (JARID1A, HOXC9), and once again MYC and E2F transcription factors.
Since these results supported such involvement of MYC and E2F activators, we decided to measure their 
expression in a more extensive dataset including 77 bladder tumours and their corresponding normal samples 
(Fig. S1A). We could confirm that the activator members of E2F family, namely E2F1 and E2F2, showed also an 
up-regulation in tumor samples compared to normal samples (Fig. S1B), confirmed by the previously described 
overexpression of E2F3a in this NMIBC dataset4. In the case of cMYC, a higher statistically significant expression 
was also detected in the bladder tumors in comparison with their corresponding healthy bladder tissue (Supl 
Fig. 1). These results support that both cMYC and E2Fs up-regulation is characteristic of NMIBC.
Differential exon expression between normal and non-invasive tumor bladder samples. Since 
Affymetrix HuGene-1_0-st-v1 arrays include several probes at exon level, we could develop a bioinformatic pipe-
line to study the differences in exon usage based on the splicing index calculation. The splicing index (SI) is the 
log ratio of the exon intensities after normalization to the gene intensity, and it was calculated for each exon for 
all the samples analyzed by Affymetrix HuGene-1_0-st-v1. After data processing, a total of 174616 exons were 
detected. Among them, 3443 showed statistically significant differences in their expression between normal and 
tumor samples (Benjamini-Hochberg multiple test correction p < 0.001), belonging to 1747 genes. GOBP anal-
yses revealed different pathways altered, including several genes belonging to Notch and Hedgehog signalling 
(Fig. 2B,C), previously reported as key for BC progression17,18. As a whole, most of the exons showing differential 
expression appeared less expressed in tumor bladder samples, suggesting a tendency of loss of exons that may lead 
to new shorter isoforms, more efficient to favour tumor progression. Since studying each new isoform expression 
and activity will be out of the current scope, and to further better understand how these AS events along different 
genes in these pathways were affecting the global Notch and Hedgehog activity levels, we decided to measure 
the expression of their corresponding readouts by RT-qPCR in the wider dataset (Fig. S1A). We could confirm 
that HES1, HEYL and HEY1 showed statistically significant decreased expression in bladder tumor compared 
with normal tissue (Fig. 3A), supporting that the alternative isoforms collaborate with the previously described 
Figure 2. Splicing index (SI) analyses using Affymetrix HuGene-1_0-st-v1 comparing each tumor bladder 
cancer sample with its corresponding normal bladder sample. (A) Genes belonging to Notch pathway showing 
alternative splicing events. HDAC9 is shown as example. Red lines represent the SI from recurrence samples and 
blue from tumor samples without recurrence development. Green boxes represent where the array probes are 
located. Yellow boxes represent exon genes. Horizontal blue lines represent the different transcripts described 
according Ensemble database. Only some of the exons (yellow boxes) have representation in the array (green 
boxes). (B) GOBP analyses showed also an important number of Hedgehog pathways genes with AS. In this 
case GLI2 gene is represented as example. Red lines represent the SI from recurrence samples and blue from 
tumor samples without recurrence development. Green boxes represent where the array probes are located. 
Yellow boxes represent exon genes. Horizontal blue lines represent the different transcripts described according 
Ensemble database. Only some of the exons (yellow boxes) have representation in the array (green boxes).
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decreased Notch activity in BC17. In the case of Hedgehog, its main read-out genes are PTCH1 together with GLI1 
and GLI2. Both GLI1 and GLI2 showed a statistically significant higher expression in tumor samples compared 
to normal bladder, while PTCH1 did not show statistically significant differences (Fig. 3B). These results support 
that the AS events along different genes in the pathway help to the previously reported activation of Hedgehog 
activity in tumor samples, favouring progression of BC18.
Differential exon expression between recurrent and non-recurrent bladder samples. Splicing 
Index (SI) was also calculated in a comparison between patient’s tumours suffering recurrence versus tumours 
without recurrence. In this case, 173812 exons could be evaluated, finding 2121 with statistically significant 
differences in expression (adjusted p-value < 0.01), belonging to 1761 genes. Gene Ontology (GOBP) analyses 
showed that most of these genes were involved in regulation of gene expression and epigenetic mechanisms (ie. 
gene silencing by miRNA, RNA processing, chromatin modification). Gene Set Enrichment Analyses (GSEA), 
using TRANSFAC database and Chip Enrichment Analyses (ChEA), showed that those genes with AS presented 
binding sites for key cancer-related transcription factors (SMAD4, STAT3, RUNX1, TP53,…), epigenetic factors 
(JARID1A, KDM5B), and again E2Fs, and MYC (Fig. 4). Therefore epigenetic factors and E2F and MYC are clearly 
involved not only in the tumor initiation but also in the recurrence development.
Alternative splicing of MDM2 and TP53 expression in NMIBC. When comparing samples from 
patients with and without recurrence, MDM2 showed several exons with statistically significant differences 
(p = 0.0004), showing a higher expression of the first and last exons in the samples from patients developing 
recurrence (Fig. 5A). This result could indicate that there is a higher proportion of shorter MDM2 alternative 
isoforms, described previously as unable to repress TP53, in recurrent tumours expression. This found, together 
with the previous result where genes with AS in recurrent samples showed binding sites for TP53, prompted us 
to check the expression of TP53, to confirm if it could be related to recurrence development. Then, its protein 
expression was evaluated in a Tissue MicroArray (TMA) containing the whole patients’ cohort (Fig. S1A). In this 
way, we detected tumours with positive and with negative staining, as shown in Fig. 5D. Interestingly, we could 
confirm that those patients with positive stained tumours (high expression of TP53) presented a higher likelihood 
of suffering recurrence (p = 0.033*), supporting that TP53 expression could be a good predictable biomarker for 
recurrence. Using the RNAseq data from Hedegaard et al.’s study, where 476 NMIBC are included19, we could 
confirm that TP53 appeared more expressed in more advanced stages (Ta vs T1, p = 0.041), showing the same 
tendency for high-grade tumours (p = 0.059), and for MIBC tumours, although not reaching the statistical signif-
icance probably due to the few invasive samples included (16 T2-4 vs 457 Ta-T1).
Based on these results, we decided to examine if the differences in TP53 expression could be also caused 
by DNA mutations. NGS-based analysis of TP53 mutations was carried out using the TP53 MASTR from 
Multiplicon for those patients of the same dataset with DNA available (n = 61, Fig. S1A), targeting SNVs and 
small indels in the coding region of TP53. Of the 61 NMIBC patient samples, 40.4% presented some SNVs, find-
ing a total of 34 different SNVs in the whole dataset. Regarding the type effect of these SNVs, 52.9% were missense 
Figure 3. RT-qPCR analyses using TBP as gene normalizer. (A) Notch read-out (HES1, HEYL, and HEY1) gene 
expressions were measured, finding decreased expressions in tumor samples compared with paired normal 
samples. (B) Hedgehog read-out (GLI1, GLI2, and PTCH1) gene expressions were measured, finding increased 
expression in tumor samples.
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variant, 23.5% intron variants, 11.8% synonymous variant, 5.9% splice acceptor variant, 2.95% frameshift variant, 
and 2.95% stop gained variants (Fig. 5B). The SNV presence was checked to find possible association with the 
patients’ clinic-pathological characteristics. Thus, we found statistically significant associations with the tumor 
stage (p = 0.017*), the tumor grade (p = 0.026*), and close to the statistical significance in the case of disease 
specific survival (dss) (p = 0.056). These differences were even more supported when only those SNVs in cod-
ing sequences were considered (29.8% of patients), finding statistically significant associations with tumor stage 
(p = 0.007**), tumor grade (p = 0.007**), and disease specific survival (p = 0.041*).
In addition, two population variants were found: a missense variant (rs1042522) in codon 72, and one intron 
variant (rs146534833). In the case of the intron, the variation consisted of an insertion variation that appeared 
in heterozygosis in 73.8% of the cases, in homozygosis in 3.3%, and absent in 22.9% of the patients. In the case of 
the variant in the codon 72, it is a common polymorphism, encoding either proline (cCc) or arginine (cGc). In 
our dataset, the allelic frequencies for the homozygous (C/C) were from 0.998 to 0.913 (mean = 0.992), while in 
the case of heterozygous (G/C) were from 0.291 to 0.845 (mean = 0.598). Most of the cases were homozygous for 
proline triplet (cCc: 64.7%). Remarkably, when they were compared to those heterozygous proline/arginine (cGc: 
29.4%), homozygous displayed a better free recurrence survival being statistically significant (Fig. 5C).
Discussion
Around 70–80% Non-Muscle Invasive Bladder Cancer (NMIBC) patients will suffer tumor recurrence after first 
surgical treatment. Therefore, it represents an important challenge for national health systems due to the con-
sequent associated high costs for the treatment and the required continuous follow-up. In the present work, we 
found a differential gene expression pattern between tumor and normal bladder cancer samples. Expression anal-
yses revealed a clear up-regulation of c-MYC and E2F transcription factor in tumor samples compared to their 
corresponding normal tissues showing also a correlation with splicing factors.
Regarding E2F activation in BC, E2F3a had already been earlier claimed as BC oncogene20,21. Previous data4 
in NMIBC already showed an upregulation of E2F3a in tumor samples and our current results support that the 
other two E2F activator family members, E2F1 and E2F2, are also over-expressed in tumor samples compared 
with the corresponding normal tissue. These data confirm those found in vivo using a mouse model, called TKO 
(Triple Knock Out): when Retinoblastoma family was conditionally deleted in bladder, E2F transcription factors 
increased their expression what led to the development of non-invasive muscle tumours, molecularly very similar 
to human NMIBC4.
In the case of the increased expression found for cMYC, its up-regulation has been widely described in several 
tumor types, intimately linked to critical processes in cancer such as proliferation, apoptosis, or metastasis22,23. In 
the case of BC, it has been related to the development of gemcitabine chemo-resistance24. Interestingly, several 
Figure 4. Splicing index (SI) analyses using Affymetrix HuGene-1_0-st-v1 comparing tumor bladder cancer 
samples with and without recurrences. The deregulated genes showed bindings for important transcription 
factor according TRANSFAC database and Chip Enrichment Analyses (ChEA).
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studies have pointed towards a narrow link between MYC expression and the correct work of splicing machin-
ery25,26, so it could be very interesting to further study this relationship in the case of BC.
But transcriptome analyses not only showed the involvement of cMYC and E2F, the deregulated genes showed 
also that processes such as RNA splicing, ncRNA processing, and RNA processing were involved in tumour 
initiation. To further unravel the role of splicing, we studied which genes correlated with the expression of three 
different splicing factors, finding a high correlation with epigenetic modifiers (JARID1A, HOXC9) and again 
c-MYC and E2F1. Growing evidences have proved that AS events are involved in oncogenic processes such as 
proliferation, apoptosis, hypoxia, angiogenesis, immune escape and metastasis7,27–29. In addition, oncogenic iso-
forms generated by AS have been associated with clinical outcome and cancer risk in several tumor types9,30,31. 
In BC, particular AS events have been described associated to worse prognosis11,32. Bielli et al. have recently 
described that the expression of the splicing factor PTBP1 correlates with disease progression, poor prognosis 
and worse survival in NMIBC patients10. However, research has been generally focused on particular events and 
comprehensive analyses are scarce. Last year, He et al. described prognostic signatures using splicing events to 
predict the prognosis of MIBC patients. Here, for the first time, we focus on the differential exon usage in ear-
lier stages (NMIBC). Exons showed statistically differences in their expression (or usage) between normal and 
tumor samples. These genes belonged to fundamental bladder cancer signalling pathways such as Notch and 
Hedgehog. By studying in detail the expression of their corresponding read-out genes to try to understand the 
global effect on pathway activity caused by splicing regulation, we found a decreased expression of HES/HEY 
family in tumor samples, suggesting that AS would help to the down-regulation of Notch pathway. These data 
support the Maraver and cols’ results17 that demonstrated that bladder tumours with low levels of HES1 promoted 
more mesenchymal and invasive features, favouring tumor progression and, therefore, a worse prognosis. In the 
case of Hedgehog signalling, higher tumor expression was detected for the read-out genes GLI1 and GLI2. In this 
case, AS would support the pathway activation, helping consequently to the tumor development and spread as 
Figure 5. (A) MDM2 gene showed exons differentially expressed between patients’ samples with (red) and 
without (blue) recurrence. Red lines represent the SI from recurrence samples and blue from tumor samples 
without recurrence development. Green boxes represent where the array probes are located. Yellow boxes 
represent exon genes. Horizontal blue lines represent the different transcripts described according Ensemble 
database. (B) Classification and percentage of the SNVs detected for TP53 is patients’ samples. (C) Kaplan-
Meier curves representing the recurrence-free survival differences between homozygous and heterozygous 
patients. Heterozygous patients showed statistically worse prognosis. (D) Example of a negative (up) and a 
positive (down) protein TP53 staining. The number of patients in each category in the contingency analysis was 
included and p-value was obtained by Fisher exact test.
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previously demonstrated in BC18,33. Although particular “tumor-specific” isoforms are still to be further deter-
mined, it seems clear that the new generated isoforms helps tumor to grow and expand.
In the case of the differences in AS between patients’ tumours developing, or not, recurrence, the differences 
showed less statistical power than in the previous comparison normal versus tumor, probably due to fewer dif-
ferences among tumour samples compared to tumour vs normal, and also to the lower number of comparisons 
(28 vs 38). Still, GOBP analyses showed an involvement of classical cancer-key genes (SMAD4, STAT3, RUNX1, 
TP53,…), and again epigenetic factors (JARID1A, KDM5B), E2Fs, and MYC, as in the previous normal-tumor 
comparison. The involvement again of E2F family and cMYC indicates their important role not only for the 
tumor initiation but also in the recurrence. In a previous work4, we already described that those patients with 
higher E2F3a expression suffered more and earlier recurrences, although the same relationship is not found 
for E2F1 and E2F2. This can be explained by the highly significant and positive correlation between E2F3a and 
EZH2, the core of the epigenetic Polycomb group expression, that mediates bladder tumor recurrence4. These 
new results demonstrate that the epigenetic regulation is not only restricted to Polycomb complex, but also to 
other factors such as JARID1A and KDM5B. In fact, alterations in other family members and epigenetic factors, 
as ARID1A, UTX or TERT, have been already proposed as bad prognosis factors in BC34–37.
Among the genes with AS related to recurrence, it attracted our attention the gene MDM2, repressor of TP53. 
It showed clear differences in several exons between recurrent and non-recurrent samples. Our results showed 
that around first and last exons are more expressed in samples from patients suffering recurrences. This could 
indicate that recurrence can be favoured by shorter isoforms that span intermediate exons, keeping uniquely the 
first and last exons. These shorter isoforms have been previously described as faster transcribed and unable to 
interact with TP53 in other tumours38,39. To test this hypothesis and taken into account that deregulated genes 
showed binding sites to TP53, we decided to study TP53 protein expression. An increased protein expression 
in samples from those patients suffering tumor recurrence was detected, supporting that the shorter isoforms 
were not binding TP53 and somehow favouring recurrence. In order to check if this TP53 high expression can 
be helped by the mutational stage, we used NGS. We found a close association between mutated TP53 and more 
advanced stage and grade, similar to that already reported already in the case of MIBC14,15. However, no asso-
ciation between genomic variants and recurrence was found. Although our patient cohort includes few cases 
of exitus, our data showed that those patients with mutations in TP53 present a lower disease specific survival. 
Therefore, according our data, mutations in TP53 are more related to tumor progression and prognosis, while its 
protein expression does correlate with recurrence. These results are in agreement with those from Pietzak et al. 
that reported frequent alterations in TP53 in their NMIBC samples (21%), being more frequently altered in 
advanced stages and grades. However, when they examined recurrence with TP53 altered-tumours, alone and 
combined with MDM2 after BCG treatment, no association was detected40. Interestingly, Zhou et al. did find an 
association between overexpression in NMIBC treated with BCG and recurrence free survival41. However, this 
association has not been always determined. For example, Vetterlein et al. did not detect association between 
TP53 positivity and disease progression, although in this case only patients with pT1 tumours were considered42. 
Finally, Hedegaard et al.19 recently published the most comprehensive transcriptome analysis of NMIBC samples, 
supporting a higher TP53 expression in more advanced stages, and more frequent mutations in high-risk patients, 
according with our current results. Recently, it has been published that MDM2 can bind EZH2 in a independent 
TP53 manner43, so it would be really interesting to explore this new path in NMIBC. Curiously, when focused on 
a population variant for codon 72, the heterozygous patients showed a statistically higher probability of cancer 
recurrence. The status of this codon of TP53 has been linked to cancer progression in different tumor types44–46, 
although its value in BC needs further research in a wider dataset.
As a whole, our gene expression data indicate that an up-regulation of E2F family and MYC participates in 
both initiation and tumor progression through recurrence, regulated by epigenetic mechanisms. RNA processing 
mechanisms are crucial for bladder tumor initiation and AS events affect key pathways to favour bladder cancer 
development. Finally, an alternative splicing of MDM2 could be favouring a higher TP53 protein expression and, 
as a consequence, favouring the recurrence development. In addition, mutations in TP53 are related to advanced 
stage, grade, and worse prognosis. Therefore, these results open a new possibility to use the status of TP53 as a 
prognosis biomarker in NMIBC.
Methods
Patients. Informed consent was obtained from all patients. The Ethical Committee for Clinical Research of 
“University Hospital 12 de Octubre” approved the study. Samples and clinical united data from patients were pro-
vided by the Biobanco i+12 in the Hospital 12 de Octubre integrated in the Spanish Hospital Biobanks Network 
(RetBioH; www.redbiobancos.es), following standard operation procedures with appropriate approval of the 
Ethical and Scientific Committees. Their baseline characteristics are included in Table 1 and the sampling work-
flow is summarized in Suplementary Fig. 1A. The patients have been consecutively evaluated at the Urology 
Department of the University Hospital “12 de Octubre” and diagnosed with BC (Ta-T1-T2), following current 
European Guidelines. All experiments and methods were performed in accordance with relevant guidelines and 
regulations. The sample recollection and preservation procedures have been reported elsewhere3,4,47.
Whole transcriptome analyses and RT-qPCR. Total RNA was isolated using miRNeasy Mini Kit 
(Qiagen) according to the manufacturer’s instructions and DNA was eliminated (RNAse-Free DNAse Set 
Qiagen). Genome-wide transcriptome experiments were performed using the Affymetrix HuGene-1_0-st-v1 
microarray at the Genomics Facility of the Cancer Research Center (Salamanca, Spain) using standard pro-
cedures as previously reported4. Datasets have been deposited in GEO (GSE38264). Gene Ontology and Chip 
Enrichment Analysis were performed using Enrich webtool (http://amp.pharm.mssm.edu/Enrichr/). Gene Set 
Enrichment Analysis (GSEA) was performed using the MSignature and Motif databases. To analyse relative gene 
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expression patterns, PTM (Pavlidis Template Matching) test was used. RNA-Seq data from the most extensive and 
comprehensive transcriptome analysis for NMIBC were also analysed, where 476 samples are included19.
For RT-qPCR analyses, reverse transcription was performed using the Omniscript RT Kit (Qiagen) and a 
primer specific for each of all genes of interest using 10 ng of total RNA. The sequences of the specific oligonucle-
otides used are listed in Table 2. qPCR was carried out in a 7500 Fast Real Time PCR System using Go Taq PCR 
master mix (Promega) and 1 µL of cDNA as a template. Melting curves were performed to verify specificity and 
absence of primer dimerization. Reaction efficiency was calculated for each primer combination, and TBP gene 
was used as reference gene for normalization48.
Exon array data analysis. Affymetrix HuGene-1_0-st-v1 microarray probe signals were summarised into 
probeset signals to provide a measure of expression of individual exons and observe differential exon inclu-
sion or skipping using Bioconductor library “oligo”. Array quality evaluation was performed using Bioconductor 
library “arrayQualityMetrics”. RMA (Robust Multi-array Analysis) algorithm was used for the normalization 
and summarization of the data. Three different filters were then applied: (1) to eliminate those probes with a 
‘crosshyb_type’ different of 1 (probes that hybridise to sequences other than the target sequence). (2) Following 
the Affymetrix technical note49, a probeset could be considered detected when the DABG (‘Detected above back-
ground’) p < 0.05 in ~50% of the samples of at least one group. Based on this, APT command was used to apply 
this filter following to Lockstone50. (3) Those exons unique for a transcript were eliminated. Once data were fil-
tered, Splicing Index (SI) was calculated as the log2 ratio of exon to gene intensity. Finally, statistically differences 
were detected using the “Limma” R package from Bioconductor. Multiple testing correction was applied using 
the Bonferroni adjustment.
Tissue microarray (TMA) and Immunohistochemistry. The construction and analysis of tissue 
microarray containing all these human samples has been reported elsewhere4,47. At least two representative 
duplicate cores for each case were scored. Inmunohistochemistry analysis was carried out using the monoclonal 
mouse anti-human p53 (DO07, Agilent-Dako). Signal was amplified using avidin-peroxidase (ABC Elite Kit; 
Vector Labs), and peroxidase was visualized using 3,30-diaminobenzidine as a substrate (DAB kit, Vector Labs). 
Negative control slides were obtained by replacing primary antibodies with PBS (data not shown). Scoring of the 
results and selection of the thresholds, internal controls for reactivity of each antibody, and tissue controls for the 
series were done according to previously published methods4,47.
Genomic TP53 analysis. DNA was obtained using DNeasy Blood & Tissue Kit from Qiagen following man-
ufacturer’s instructions. In order to identify single nucleotide variant (SNVs) and small indels in the coding region 
of TP53 (excluding promoter 5′ or 3′ UTR), the TP53 MASTR molecular assay from Multiplicon (Agilent) was 
used. The pipeline for SNV calling consisted on the mapping of the raw reads using the software package BWA 
followed by SNV calling using SAMtools mpileup command. The following quality-filter criteria were applied to 
VCF files: all variants should present a value in the QUAL field >= 20, total DP4 >= 20, and definitive genotype 
GT:PL >= 100. Finally, Ensembl Variant Effect Predictor (VEP, release 75) was used for the variant annotations.
Patients (n) 82*
Age median (range) 72.4 years (49–89)





Currently smoker = 27













Alterations in normal mucosa
Dysplasia = 6
Metaplasia = 1
Glandular cystitis = 1
Table 1. Baseline characteristics of patients. ND: no data. *This is the total number of patients included in the 
study. The number of tumor samples varies in each analyses depending on the required material available. See 
Supplementary Fig. 1.
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Statistical analysis. Comparisons between normal and its corresponding tumor samples were studied by 
paired sample T-test. Contingency analyses were made using the Fisher exact test. Recurrence and disease free 
survival analyses were performed using the Kaplan–Meier method and statistical differences between the patient 
groups were tested by the log-rank test. For RNA-Seq analyses from Hedegaard et al.19, FPKM (Fragments Per 
Kilobase Million) data was compared between clinical characteristics using T-test analyses, according a previous 
Levene test. SPSS 17.0 and GraphPad Prism 6.0 software were used. For the differential exon usage analysis, 
Limma and Bonferroni multiple testing correction were done in R.
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